bevacizumab

{
  "id": "MLC-T-ONC-001018",
  "term": "bevacizumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug that binds to the protein VEGF to help keep new blood vessels from forming and is used to treat many different types of cancer. Bevacizumab is used under the brand names Alymsys, Mvasi, Avastin, and Zirabev, alone or with other drugs, to treat certain types of cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), and glioblastoma (a type of brain cancer). The Alymsys and Avastin brands of bevacizumab are also used to treat certain types of ovarian epithelial, fallopian tube, and primary peritoneal cancer. The Avastin brand is also used to treat certain types of hepatocellular carcinoma (a type of liver cancer). Bevacizumab is also being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of antiangiogenesis agent and a type of monoclonal antibody.",
    "A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels."
  ],
  "abbreviation": "rhuMab-VEGF",
  "synonyms": [
    "bevacizumab-maly",
    "bevacizumab biosimilar RPH-001",
    "recombinant humanized anti-VEGF monoclonal antibody",
    "BP102 biosimilar",
    "bevacizumab biosimilar QL 1101",
    "bevacizumab biosimilar CT-P16",
    "anti-VEGF humanized monoclonal antibody",
    "bevacizumab biosimilar FKB238",
    "bevacizumab biosimilar LY01008",
    "immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer",
    "anti-VEGF rhuMAb",
    "bevacizumab biosimilar BEVZ92",
    "bevacizumab biosimilar HLX04",
    "bevacizumab awwb",
    "bevacizumab biosimilar HD204",
    "bevacizumab biosimilar ABP 215",
    "bevacizumab biosimilar IBI305",
    "bevacizumab biosimilar QL1101",
    "bevacizumab biosimilar MIL60",
    "bevacizumab biosimilar MYL-1402O",
    "bevacizumab biosimilar BI 695502",
    "bevacizumab biosimilar Zirabev",
    "bevacizumab biosimilar GB-222",
    "bevacizumab biosimilar CBT 124",
    "bevacizumab biosimilar SCT501",
    "anti-VEGF monoclonal antibody SIBP04",
    "BAT1706 biosimilar",
    "bevacizumab biosimilar Mvasi",
    "bevacizumab-adcd",
    "bevacizumab biosimilar BAT1706"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bevacizumab/"
}